SCH66336: a Phase II randomised, open-label study of SCH66336 and an Active Reference Agent Gemcitabine in Patients with Metastic Adenocarcinoma of the Pancreas
SCH66336: a Phase II randomised, open-label study of SCH66336 and an Active Reference Agent Gemcitabine in Patients with Metastic Adenocarcinoma of the Pancreas